Evidence map›Paper›PMID 42563607›Full record

ArticleJACC. Heart failure2026

Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV: Insights From the CAVIAR Trial.

Kosei Terada, Kuniaki Takahashi, Kiran K Khush, Takeshi Nishi, Joshua W Knowles, Anette Skoda, Brandon Varr, Christopher Woo, Yasuhiro Honda, William F Fearon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kosei TeradaDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
Kuniaki TakahashiDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
Kiran K KhushDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
Takeshi NishiDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
Joshua W KnowlesDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; Stanford Diabetes Research Center, Stanford Prevention Research Center, Palo Alto, California, USA.
Anette SkodaDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
Brandon VarrKaiser Permanente, Santa Clara, California, USA.
Christopher WooKaiser Permanente, Santa Clara, California, USA.
Yasuhiro HondaDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
William F FearonDivision of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; VA Palo Alto Health Care System, Palo Alto, California, USA. Electronic address: wfearon@stanford.edu.

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Characterization of novel insulin resistance genes by gene editing, high-throughput phenotyping and in vivo studiesR01DK120565 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$3.2M
Mechanisms of NAT2 Regulation of Insulin Resistance and Mitochondrial DysfunctionR01DK116750 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$2.4M
Beyond GWAS of insulin resistance: An integrated approach to translate genetic association to functionR01DK106236 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2016 to 2020
$2.4M
Molecular Mechanisms of Insulin Resistance Associated LociR01DK107437 · NIDDK · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2016 to 2019
$2.2M
Molecular Mechanisms of Insulin Resistance Associated LociR01DK137889 · NIDDK · STANFORD UNIVERSITY · PI Joshua Wiley Knowles · 2024 to 2026
$1.8M
PCSK9 Inhibition after Heart TransplantationR33HL139929 · NHLBI · STANFORD UNIVERSITY · PI FEARON, WILLIAM F · 2020 to 2023
$1.8M
Fractional flow reserve versus Angiography for Multivessel Evaluation (FAME) 3 ExtendedR01HL179196 · NHLBI · STANFORD UNIVERSITY · PI WILLIAM F FEARON · 2025 to 2026
$1.5M
PCSK9 Inhibition after Heart TransplantationR61HL139929 · NHLBI · STANFORD UNIVERSITY · PI FEARON, WILLIAM F · 2019 to 2019
$436k
NHLBI NIH HHS R01 HL179196NHLBI NIH HHS R33 HL139929NHLBI NIH HHS R61 HL139929NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK106236NIDDK NIH HHS R01 DK107437NIDDK NIH HHS R01 DK116750NIDDK NIH HHS R01 DK120565NIDDK NIH HHS R01 DK137889
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiac allograft vasculopathyheart transplantationintravascular ultrasoundlipid phenotypePCSK9 inhibition

Identifiers

PMID42563607
PMCPMC13454967

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.